Autopsy report · NCT03886493

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

“Low accrual due to COVID-19 pandemic.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 1 year 1 month before it stopped.
• 7 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

Dupilumab

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis
  “Slow accrual due to COVID-19 and lower accrual than expected.” (84% match in meaning)
• BRIDGE Device for Treatment of Opioid Withdrawal
  “Due to COVID-19 pandemic” (77% match in meaning)
• High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Bulimia and Anorexia Nervosa
  “COVID-19 pandemic restrictions.” (75% match in meaning)
• Sustaining the Reach of a Scalable Weight Loss Intervention Through Financial Incentives
  “Due to the COVID-19 pandemic” (75% match in meaning)
• Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors
  “due to COVID-19” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.